CA2674542A1 - Neuroprotection by blood flow stabilization - Google Patents

Neuroprotection by blood flow stabilization Download PDF

Info

Publication number
CA2674542A1
CA2674542A1 CA002674542A CA2674542A CA2674542A1 CA 2674542 A1 CA2674542 A1 CA 2674542A1 CA 002674542 A CA002674542 A CA 002674542A CA 2674542 A CA2674542 A CA 2674542A CA 2674542 A1 CA2674542 A1 CA 2674542A1
Authority
CA
Canada
Prior art keywords
blood flow
neurotoxicity
vasodilator
neurodegeneration
anticoagulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002674542A
Other languages
French (fr)
Other versions
CA2674542C (en
Inventor
Susana N. Martinez-Conde
Stephen L. Macknik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dignity Health
Original Assignee
Catholic Healthcare West
Susana N. Martinez-Conde
Stephen L. Macknik
Dignity Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catholic Healthcare West, Susana N. Martinez-Conde, Stephen L. Macknik, Dignity Health filed Critical Catholic Healthcare West
Publication of CA2674542A1 publication Critical patent/CA2674542A1/en
Application granted granted Critical
Publication of CA2674542C publication Critical patent/CA2674542C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Abstract

A treatment is disclosed for alleviation or prevention of abnormal blood flow to various organs such as the eye, brain, kidneys, heart, feet and other tissues of organs with fine vascular networks that can lead to neurodegeneration as is seen in wet age- related macular degeneration (AMD), epilepsy and diabetes, in which an effective amount of a blood flow regulatory drug is administered to a subject in need of it. Illustrative blood flow regulatory drugs include anticoagulants and vasodilators, and their mixtures.

Claims (15)

1. A method for treatment of neurotoxicity or neurodegeneration caused by abnormal blood flow that comprises administration of an effective amount of a blood flow regulatory drug to a subject in need thereof.
2. The method according to claim 1, wherein said administration is carried out a plurality of times.
3. The method according to claim 1, wherein said subject is a human patient.
4. The method according to claim 1, wherein said blood flow regulatory drug is an anticoagulant, a vasodilator, or a mixture thereof.
5. The method according to claim 4, wherein said blood flow regulatory drug is an anticoagulant.
6. The method according to claim 5, wherein said anticoagulant is selected from the group consisting of heparin, an NSAID and a clot-dissolving enzyme.
7. The method according to claim 4, wherein said blood flow regulatory drug is a vasodilator.
8. The method according to claim 7, wherein said vasodilator is selected from the group consisting of an organonitrate, a phosphodiesterase inhibitor, an .alpha.-blocker, an ergot alkaloid, an antihypertensive agent, and prostaglandin E1.
9. The method according to claim 7, wherein said vasodilator is prostaglandin E1, an organonitrate or phentolamine.
10. The method according to claim 1, wherein said neurotoxicity or neurodegeneration is caused by wet age-related macular degeneration.
11. The method according to claim 1, wherein said neurotoxicity or neurodegeneration is caused by epilepsy.
12. The method according to claim 1, wherein said neurotoxicity or neurodegeneration is caused by diabetes.
13. A method for treatment of neurotoxicity or neurodegeneration caused by abnormal blood flow in a human patient having wet age-related macular degeneration that comprises administration of an effective amount of a blood flow regulatory drug that is an anticoagulant, a vasodilator, or a mixture thereof to said patient.
14. The method according to claim 13, wherein said administration is carried out multiple times.
15. A method for treatment of neurotoxicity or neurodegeneration caused by abnormal blood flow in a human patient having epilepsy that comprises administration of an effective amount of a blood flow regulatory drug that is an anticoagulant, a vasodilator, or a mixture thereof to said patient.

15. The method according to claim 15, wherein said administration is carried out multiple times.

17. A method for treatment of neurotoxicity or neurodegeneration caused by abnormal blood flow in a human patient having diabetes that comprises administration of an effective amount of a blood flow regulatory drug that is an anticoagulant, a vasodilator, or a mixture thereof to said patient.

18. The method according to claim 17, wherein said administration is carried out multiple times.
CA2674542A 2006-12-21 2007-12-20 Neuroprotection by blood flow stabilization Expired - Fee Related CA2674542C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87635406P 2006-12-21 2006-12-21
US60/876,354 2006-12-21
US97750107P 2007-10-04 2007-10-04
US60/977,501 2007-10-04
PCT/US2007/088436 WO2008080009A2 (en) 2006-12-21 2007-12-20 Neuroprotection by blood flow stabilization

Publications (2)

Publication Number Publication Date
CA2674542A1 true CA2674542A1 (en) 2008-07-03
CA2674542C CA2674542C (en) 2012-10-09

Family

ID=39563221

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2674542A Expired - Fee Related CA2674542C (en) 2006-12-21 2007-12-20 Neuroprotection by blood flow stabilization

Country Status (4)

Country Link
US (1) US20080175831A1 (en)
EP (1) EP2115106A4 (en)
CA (1) CA2674542C (en)
WO (1) WO2008080009A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376183B2 (en) 2014-04-29 2019-08-13 Dignity Health Systems and methods for non-intrusive drug impairment detection
US10743806B2 (en) 2014-06-11 2020-08-18 Dignity Health Systems and methods for non-intrusive deception detection

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189166A1 (en) * 2010-01-29 2011-08-04 John Boucher Methods of treating hemorheologic abnormalities in mammals

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
JP2001261575A (en) * 2000-03-13 2001-09-26 General Hospital Corp Method for regulating vasoconstriction and its composition
ATE401082T1 (en) * 2001-09-11 2008-08-15 Asahi Kasei Pharma Corp MEDICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CEREBROVASCULAR DISORDERS
US20060194810A1 (en) * 2004-04-30 2006-08-31 Bijan Almassian Methods of treating ischemic related conditions
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376183B2 (en) 2014-04-29 2019-08-13 Dignity Health Systems and methods for non-intrusive drug impairment detection
US11344226B2 (en) 2014-04-29 2022-05-31 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods for non-intrusive drug impairment detection
US10743806B2 (en) 2014-06-11 2020-08-18 Dignity Health Systems and methods for non-intrusive deception detection
US11759134B2 (en) 2014-06-11 2023-09-19 Arizona Board Of Regents On Behalf Of Arizona State University Dignity Health Systems and methods for non-intrusive deception detection

Also Published As

Publication number Publication date
CA2674542C (en) 2012-10-09
EP2115106A4 (en) 2010-03-10
EP2115106A2 (en) 2009-11-11
WO2008080009A3 (en) 2008-10-09
US20080175831A1 (en) 2008-07-24
WO2008080009A2 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
Gil et al. Clinical outcome of hemoperfusion in poisoned patients
CA2621582A1 (en) Prevention of hypotension and stabilization of blood pressure in hemodialysis patients
JP2008542206A5 (en)
WO2005063745A8 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
WO2008008340A3 (en) System and method for a low profile vibrating plate
JP2011516428A5 (en)
WO2002026223A3 (en) Catecholamine pharmaceutical compositions and methods
WO2006023630A3 (en) The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
WO2009127974A3 (en) Pharmaceutical formulation for treating cardiovascular disease
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
WO2009093264A3 (en) Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc.
JP2014500280A5 (en)
CA2674542A1 (en) Neuroprotection by blood flow stabilization
JP2009507055A5 (en)
WO2010071320A3 (en) Controlled-release composition for producing sustained-release preparation containing udenafil
WO2002074246A3 (en) Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
WO2005089736A3 (en) Methods for treating inflammatory and autoimmune diseases
WO2008088536A8 (en) Differential drug release from a medical device
CN105030807B (en) Niacinamide ribose is preparing the application in treating Imaging in Patients with Cerebral Ischemia Disease drug
WO2006079625A3 (en) Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
CN116829168A (en) Use of cyclosporin analogs as antithrombotic agents
WO2006087420A3 (en) A method for treating heart failure
RU2012116226A (en) Broncholytic agent based on prostaglandin
US20190183851A1 (en) Use of 3,4,7-trihydroxyisoflavone or 3-methoxydaidzein in preparation of drug for inhibiting platelet aggregation and thrombosis
WO2005030785A3 (en) Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therapeutics

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20191220